Search filters

FoRx Therapeutics AG raises EUR 10M Seed-Financing round

FoRx Therapeutics AG, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round led by M...

Numab and Sunshine Guojian form partnership

3SBio Inc.’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) and Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific...

ImmunOs Therapeutics AG raises CHF 15M in Series A Financing

ImmunOs Therapeutics AG, a Swiss biotechnology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15 million....

EraCal Therapeutics AG Closes Seed Financing Round

EraCal Therapeutics AG, established as a spin-off from the University of Zurich and Harvard University, completes an oversubscribed seed financing round. Investors included Bernina BioInvest, Redalpine, the UZH Life Sciences Fund...

T3 Pharmaceuticals AG closes its second financing round

T3 Pharmaceuticals AG, a Basel-based company focusing on immuno-oncology, closes its second financing round of over 12M CHF with existing investors joined by Boehringer Ingelheim Venture Fund (BIVF) and Reference Capital SA.

VISC...

KLV Verlag AG sold to Westermann Group

KLV Verlag AG in St. Gallen, specialising in teaching materials, workbooks and non-fiction books for vocational training for vocational schools and grammar schools, will be sold retroactively as of January 1, 2019, to the...

ALENTIS Therapeutics raises CHF 12.5m in Series A Financing

ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5 million. ALENTIS’ lead program is a...

Cooperation between Spaeter/RUWA and Peikko

Spaeter AG, based in Basel, a Swiss wholesaler in the construction and ancillary construction sector, and its subsidiary RUWA-Drahtschweisswerk AG have entered into a comprehensive cooperation in Switzerland with the Finnish...

Anaveon closes CHF 35 m Series A financing

Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch,...

Oculis in-licenses novel phase II-stage Anti-TNF alpha antibody fragment

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The...

You are currently offline. Some pages or content may fail to load.